Table 3 Incidence of all non-hematological and hematological toxic effects.

From: An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)

Characteristics

non-CHT group (n = 62)

CHT group (n = 66)

P

Differentiation syndrome

10 (16%)

11 (17%)

0.87

Neutropenia (grade 3–4 lasting > 15 days)

5 (8%)

11 (17%)

0.14

Thrombocytopenia (grade 3–4 lasting > 15 days)

20 (32%)

30 (45%)

0.13

Pneumonia and fever

31 (50%)

35 (53%)

0.87

Hepatic toxicity (grade 3–4)

5 (8%)

5 (8%)

1.00

Renal toxicity (grade 3–4)

1 (2%)

0

1.00

Cardiac toxicity (grade 3–4)

1 (2%)

8 (12%)

0.03

QTc prolongation (grade 3–4)

0

1 (2%)

1.00

Skin toxicity (grade 1–3)

9 (15%)

11 (17%)

0.74

  1. Skin toxicity occurred during consolidation and maintenance therapy, all of other toxic effects occurred during induction therapy.
  2. CHT chemotherapy.
Back to article page